Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Noteworthy Tuesday Option Activity: URI, NEM, EA
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in United Rentals Inc (Symbol: URI), where a
Noteworthy Tuesday Option Activity: BKNG, NVDA, VLO
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Booking Holdings Inc (Symbol: BKNG), where a
Tuesday’s ETF with Unusual Volume: REMX
The Rare Earth/Strategic Metals ETF is seeing unusually high volume in afternoon trading Tuesday, with over 326,000 shares traded versus three month average volume of
TTWO November 17th Options Begin Trading
Investors in Take-Two Interactive Software, Inc. (Symbol: TTWO) saw new options become available today, for the November 17th expiration. One of the key inputs that
Comerica is Oversold | Nasdaq
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks
Insiders Buy the Holdings of MORT ETF
A look at the weighted underlying holdings of the Mortgage REIT Income ETF (Symbol: MORT) shows an impressive 17.9% of holdings on a weighted basis
C3 AI plunges 15% as short seller Kerrisdale says it sent a letter to auditor on issues By Investing.com
© Reuters. C3 AI (AI) plunges 15% as short seller Kerrisdale says it sent a letter to auditor on issues By Senad Karaahmetovic Shares of C3.ai
KEN Ex-Dividend Reminder – 4/6/23
Looking at the universe of stocks we cover at Dividend Channel, on 4/6/23, Kenon Holdings Ltd (Symbol: KEN) will trade ex-dividend, for its annual dividend
Core Laboratories Reaches Analyst Target Price
In recent trading, shares of Core Laboratories N.V. (Symbol: CLB) have crossed above the average analyst 12-month target price of $22.50, changing hands for $23.57/share.
Arbutus files patent infringement lawsuit against Pfizer/BioNTech over COVID shots By Reuters
© Reuters. FILE PHOTO: Pfizer logo is seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo (Reuters) -Arbutus Biopharma on Tuesday sued